Novo Nordisk seeks national health insurance coverage for Wegovy in Korea
Novo Nordisk Korea has applied to the Health Insurance Review and Assessment Service for reimbursement of its obesity drug Wegovy, pharmaceutical industry sources said Tuesday. This move aims to significantly lower treatment costs and intensify competition in Korea's obesity drug market, where it seeks to regain ground against Eli Lilly's market-leading Mounjaro and Hanmi Pharmaceutical's upcoming homegrown rival, Eppe.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Goldman Sachs Report: Hedge Funds Reduce Tech Holdings, but Mag 7 Positions Hit Record Highs, Revealing a Structural Divergence Between Market Confidence and Positioning Data
-
2
Saudi Arabia plans to increase its oil export capacity beyond the Persian Gulf to 10 million barrels per day within two years, and will temporarily use natural gas pipelines for oil transport.
-
3
Seoul shares plunge over 3% to 6,384.24 points on tech sell-off, extending losing streak to fourth session
-
4
XRP Ledger Foundation Faces Backlash Over Low Bounty Payouts for Critical Bug
-
5
Iran escalates attacks on "non-compliant" oil tankers, putting crude oil shipments through the Strait of Hormuz under pressure, with multiple empty VLCCs avoiding the Persian Gulf.
-
6
The 2026 Nobel Memorial Prize in Economic Sciences has been awarded to Robert E. Hall and Michael Woodford.
-
7
Nobel prize in economics awarded to Robert E. Hall and Michael Woodford
-
8
Brake pedal failure during testing of Huawei-backed Chinese luxury EV, Maextro V800, prompts Chinese regulators to issue new draft rules.
-
9
Iran's Revolutionary Guard Corps states it has designated the "US-UAE" Strait of Hormuz oil shuttle system as a clear target.
-
10
Harneys and dropRWA plan Bermuda tokenized catastrophe bond issuance next year, aiming to bridge disaster-insurance gap
Markets Today
Recommended Reading


